Boston, MA 09/02/2014 (wallstreetpr) – Primary endpoints results of the clinical trial of Neural Cardiac Therapy for Heart Failure (NECTAR-HF) were released by Boston Scientific Corporation (NYSE:BSX) recently. The company called this as the one-of-its-kind sham-controlled test based on a random basis and looking into Vagus Nerve Stimulation (VNS) for the heart failure patients. The results were presented at the 2014 European Society of Cardiology Congress which took place in Barcelona, Spain. European Heart Journal will soon publish the results as well.
About the Study Involving NECTAR-HF Clinical Trial
In the study, 96 Class II-III patients of New York Heart Association (NYHA) suffering from ejection fraction of below 35% and heart failure were being evaluated. All these patients were asked to continue with their medical treatment, but at the same time, were randomized in the ratio of 2:1 to treatment or sham, respectively.
Even though the quality of life metrics demonstrated a crucial symptomatic improvement, but there was a lack of any imperative effect on most important and less important endpoint measures associated with the cardiac remodelling as well as functional capacity of heart failure patients.
After having received 6-months of randomization, the control patients start receiving active therapy. Thereafter, all patients go through 18 months for the safety endpoint.
Statement from NECTAR-HF Principal Investigator
The NECTAR-HF Principal Investigator, Prof. Zannad said that the execution, as well as careful design of NECTAR-HF, led to the creation of high-quality data. He added that this will help in getting better understanding of role of VNS in HF patients’ treatment.
Prof. Zannad also added, “NECTAR-HF should be the benchmark for future studies of novel device therapies” that are involved in the treatment of heart failure.”
Statement from Rhythm Management for Boston Scientific
The Chief Medical Officer of Rhythm Management for Boston Scientific Corporation (NYSE:BSX), Kenneth Stein, M.D. in this context said that advancement of clinical studies, exploration of new therapies as well as provision of new diagnostic options for HF patients is the commitment of Boston Scientific Corporation (NYSE:BSX).
